Eli Lilly’s stock plummets over missed sales forecasts for Mounjaro, Zepbound – what’s next for the pharma giant?
Eli Lilly & Co. has faced a dramatic drop in its stock price, tumbling over 10% following a critical earnings report that highlighted missed revenue ... Read More
vTv Therapeutics and OnKure part ways, dissolving pivotal cellular drug agreement
vTv Therapeutics, a clinical-stage biopharmaceutical company known for its innovative approach in diabetes treatment, and OnKure Therapeutics, an oncology-focused pharmaceutical company, have announced the termination ... Read More
Eli Lilly to expand manufacturing with $1bn investment in Ireland to boost Alzheimer’s drug production
Eli Lilly and Company (NYSE: LLY) has announced a substantial $1 billion investment to expand its Limerick, Ireland, manufacturing site, which will increase the production ... Read More
TUXEDO-2 trial wraps up enrolment: Could Sahajanand Medical Technologies’ stent revolutionise diabetes care?
In a landmark achievement for cardiovascular medicine, Sahajanand Medical Technologies has announced the successful completion of patient enrolment for the TUXEDO-2 clinical trial in India. ... Read More
Setback for diabetes innovation: FDA puts brakes on Novo Nordisk’s once-weekly insulin icodec
Novo Nordisk announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application for its ... Read More
Unveiling the Therapeutic Power of Agnimantha: A Holistic Approach to Wellness
Agnimantha, scientifically recognized as Premna integrifolia L., is a traditional medicinal herb that plays a crucial role in Ayurvedic medicine. Known by various names such ... Read More
Novo Nordisk’s Fiasp gains FDA approval for fast-acting insulin, enhancing diabetes management in US
Novo Nordisk, a leading Danish pharmaceutical company, has secured a significant regulatory milestone with the US FDA approval of its innovative fast-acting mealtime insulin aspart ... Read More
FDA approves Novo Nordisk’s Victoza for heart disease treatment in type 2 diabetes patients
In a significant advancement for diabetes care, Danish pharmaceutical giant Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) to use ... Read More